GlassScriptPhysician profile
Enrique A Wulff
NPI 1114030186
$611.19
in general payments reported to CMS, 2019-2025
12 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $131 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.28 | 2025 | |
| Lundbeck LLC | $107.45 | 2024-2025 | Vyepti, Rexulti |
| Pfizer INC. | $97.34 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $58.55 | 2024-2025 | Ingrezza |
| Eisai INC. | $47.65 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $44.04 | 2025 | Nuplazid |
| Lilly USA, LLC | $25.82 | 2024 | Kisunla, Amyvid |
| Vanda Pharmaceuticals INC. | $21.03 | 2025 | Ponvory |
| Neurelis, INC. | $19.05 | 2025 | Valtoco |
| Azurity Pharmaceuticals, INC. | $16.82 | 2025 | |
| Harmony Biosciences LLC | $15.67 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $13.49 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Wulff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.